Sort
64,565 grants matching “drug discovery”
Therapeutic antibodies for treating liver fibrosis
$999,999Lauren Jennifer Schwimmer · Abalone Bio, Inc. · R44 · FY2023 · DK
Therapeutic antibodies for treating liver fibrosis
$999,999Lauren Jennifer Schwimmer · Abalone Bio, Inc. · R44 · FY2022 · DK
Therapy Against Recalcitrant C. albicans Infection
$999,998Thomas A Dahl · Arietis · R44 · FY2011 · AI
Preclinical development of a potent D-peptide RSV inhibitor
$999,998Brett D Welch · Navigen, Inc. · R44 · FY2017 · AI
Assessing the polypharmacology of kinase inhibitors by transcription factor activity profiling
$999,998Sergei S Makarov · Attagene, Inc. · R44 · FY2021 · GM
Third line treatment of drug resistant FLT3-positive acute myeloid leukemia with a novel FLT3 kinase inhibitor
$999,998Frederick Wayne Holtsberg · Kinarx, Llc · R44 · FY2021 · CA
DEVELOPMENT OF A WNT PATHWAY INHIBITOR FOR METASTATIC COLORECTAL CANCER
$999,998Darren Orton · Stemsynergy Therapeutics, Inc. · R44 · FY2018 · CA
Mid Southern Primary Care Networks Node
$999,998Li-Tzy T Wu · Duke University · UG1 · FY2019 · DA
Preclinical development of a potent D-peptide RSV inhibitor
$999,998Brett D Welch · Navigen, Inc. · R44 · FY2018 · AI
Assessing the polypharmacology of kinase inhibitors by transcription factor activity profiling
$999,998Sergei S Makarov · Attagene, Inc. · R44 · FY2020 · GM
Optimization of orally bioavailable inhibitors for the treatment of COVID-19 and other human coronavirus infections
$999,998Glen Andrew Coburn · Venatorx Pharmaceuticals, Inc. · R44 · FY2025 · AI
High-content behavioral phenotyping of model organisms in three dimensions with a gigapixel microscope
$999,997Mark Harfouche · Ramona Optics, Inc. · R44 · FY2024 · OD
A novel protein engineering tool for rapid manufacturing of designer nucleosomes
$999,997Michael-Christopher Keogh · Epicypher, Inc. · R44 · FY2018 · CA
Rapid dissection of the biosynthesis of antiMRSA antibiotics produced in co-culture by extremophilic fungi through the development of Fungal Artificial Chromosomes
$999,997Chengcang Charles Wu · Intact Genomics, Inc. · R44 · FY2022 · AI
Micronized salsalate in a parenteral formulation is a safe and effective analgesic for acute postoperative pain management
$999,994Joel Steven Ross · Rh Nanopharmacueticals L.L.C. · R44 · FY2021 · NS
Development of Nociceptin Receptor Agonists for Alcohol Use Disorders, Period of Performance 09/15/15 - 09/14/17; CPFF
$999,993Nurulain Zaveri · Astraea Therapeutics, Llc · N44 · FY2015 · HD
Preclinical development of Novo29, a new antibiotic
$999,992Losee Lucy Ling · Novobiotic Pharmaceuticals, Llc · R44 · FY2019 · AI
Scale-up and Synthesis of a Tau Oligomer Inhibitor to initiate IND enabling studies for AD and ADRD
$999,982James G. Moe · Oligomerix, Inc · R44 · FY2019 · AG
DEVELOPMENT OF A WNT PATHWAY INHIBITOR FOR METASTATIC COLORECTAL CANCER
$999,981Darren Orton · Stemsynergy Therapeutics, Inc. · R44 · FY2019 · CA
Rapid structure-based software to enhance antibody affinity and developability for high-throughput screening
$999,980Steven Joseph Darnell · Dnastar, Inc. · R44 · FY2020 · AI
Novel spectinamide antibiotics for the treatment of MDR/XDR tuberculosis
$999,980Michelle M. Butler · Microbiotix, Inc · R44 · FY2014 · AI
Small Molecule Antagonists of PF4 for the Treatment and Prevention of HIT
$999,965Jay Edward Wrobel · Fox Chase Chemical Diversity Center, Inc · R44 · FY2021 · HL
Small Molecule Antagonists of PF4 for the Treatment and Prevention of HIT
$999,945Jay Edward Wrobel · Fox Chase Chemical Diversity Center, Inc · R44 · FY2019 · HL
A Chicago Biomedical Consortium Hub of Innovative Technologies for Entrepreneurship and Science (CBC - HITES)
$999,938Satish N Nadig · Northwestern University At Chicago · U01 · FY2023 · GM
Scale-up and Synthesis of a Tau Oligomer Inhibitor to initiate IND enabling studies for AD and ADRD
$999,937James G. Moe · Oligomerix, Inc · R44 · FY2020 · AG